Lebas Arthur, Le Fevre Clara, Waissi Waisse, Chambrelant Isabelle, Brinkert David, Noel Georges
Radiotherapy Department, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033 Strasbourg, France.
Radiotherapy Department, Léon Bérard Center, 28 Rue Laennec, 69008 Lyon, France.
Cancers (Basel). 2024 May 7;16(10):1789. doi: 10.3390/cancers16101789.
The prognostic factors for extremity soft-tissue sarcomas (ESTSs) treated with multimodal surgery and radiotherapy (RT) remain a subject of debate across diverse and heterogeneous studies.
We retrospectively analyzed nonmetastatic ESTS patients treated with RT between 2007 and 2020 in Strasbourg, France. We assessed local control (LC), distant control (DC), overall survival (OS), and complications.
A total of 169 patients diagnosed with localized ESTS were included. The median age was 64 years (range 21-94 years). ESTS primarily occurred proximally (74.6%) and in the lower limbs (71%). Most tumors were grade 2-3 (71.1%), deep-seated (86.4%), and had R0 margins (63.9%). Most patients were treated with helical tomotherapy (79.3%). The median biologically effective dose (BED) prescribed was 75 BEDGy (range 45.0-109.9). The median follow-up was 5.5 years. The 5- and 10-year LC, DC, and OS rates were 91.7%, 76.8%, and 83.8% and 84.2%, 74.1%, and 77.6%, respectively. According to the univariate analysis, LC was worse for patients who received less than 75 BEDGy ( = 0.015). Deep tumors were associated with worse OS ( < 0.05), and grade 2-3 and undifferentiated pleomorphic sarcoma (UPS) were linked to both shorter DC and shorter OS ( < 0.05). IMRT was associated with longer LC than 3DRT ( = 0.018). Multivariate analysis revealed that patients with liposarcoma had better OS ( < 0.05) and that patients with distant relapse had shorter OS ( < 0.0001).
RT associated with surgical resection was well tolerated and was associated with excellent long-term rates of LC, DC, and OS. Compared with 3DRT, IMRT improved local control. Liposarcoma was a favorable prognostic factor for OS. Intermediate- and high-grade tumors and deep tumors were associated with lower DC and OS.
多模式手术和放疗(RT)治疗肢体软组织肉瘤(ESTS)的预后因素在各种不同且异质性的研究中仍是一个有争议的话题。
我们回顾性分析了2007年至2020年在法国斯特拉斯堡接受放疗的非转移性ESTS患者。我们评估了局部控制(LC)、远处控制(DC)、总生存期(OS)和并发症。
共纳入169例诊断为局限性ESTS的患者。中位年龄为64岁(范围21 - 94岁)。ESTS主要发生在近端(74.6%)和下肢(71%)。大多数肿瘤为2 - 3级(71.1%)、深部(86.4%)且切缘R0(63.9%)。大多数患者接受螺旋断层放疗(79.3%)。规定的中位生物等效剂量(BED)为75 BEDGy(范围45.0 - 109.9)。中位随访时间为5.5年。5年和10年的LC、DC和OS率分别为91.7%、76.8%和83.8%以及84.2%、74.1%和77.6%。根据单因素分析,接受BEDGy小于75的患者LC较差(P = 0.015)。深部肿瘤与较差的OS相关(P < 0.05),2 - 3级和未分化多形性肉瘤(UPS)与较短的DC和较短的OS均相关(P < 0.05)。调强放疗(IMRT)与比三维适形放疗(3DRT)更长的LC相关(P = 0.018)。多因素分析显示脂肪肉瘤患者有更好的OS(P < 0.05),远处复发患者有较短的OS(P < 0.0001)。
与手术切除相关的放疗耐受性良好,且与优异的长期LC、DC和OS率相关。与3DRT相比,IMRT改善了局部控制。脂肪肉瘤是OS的有利预后因素。中高级别肿瘤和深部肿瘤与较低的DC和OS相关。